Intelisci, a leading Specialist Retained Search and Advisory firm dedicated to providing essential support to growing biotechnology companies, is pleased to announce the appointment of Dr. Neil Wishart to its esteemed Scientific Advisory Board.
Dr. Neil Wishart, PhD, brings over three decades of outstanding leadership and expertise from the pharmaceutical industry, renowned for his pioneering contributions in drug development. His remarkable career has been marked by a commitment to delivering innovative medications to patients worldwide.
Neil's comprehensive experience covers the entire lifecycle of launching new treatments, with a special focus on inflammatory conditions. This valuable expertise enhances Intelisci's ability to offer fresh insights and solutions in a crucial area for our clients.
Matt Tong, CEO of Intelisci, expressed his enthusiasm for the new addition to the team, stating, "We are thrilled to welcome Neil to our Scientific Advisory Board. His extensive experience and remarkable achievements in the biopharma industry align perfectly with our mission to provide top-tier talent solutions to biotechnology companies. Neil's expertise in drug development will undoubtedly be a tremendous asset as we continue to support the growth and success of our clients."
Throughout his career, Dr. Wishart has excelled in strategic business acumen, competitive intelligence, operational excellence, market access, line extensions, and regulatory compliance. He has played instrumental roles in cross-functional program leadership and portfolio strategy, influencing corporate strategies within global biopharma organizations.
Neil's inspiring leadership has been demonstrated through his mentorship of high-performing teams, and his extensive contributions as an inventor and researcher, evidenced by numerous patents and publications.
Neil's career highlights include his role as VP, Program Executive at EQRx, where he spearheaded the development of immunology and inflammation programs. He also served as Sr. Director, Program Management at Flexion Therapeutics, overseeing early development pipeline assets. At Sage Therapeutics, Neil held the position of Sr. Director, Portfolio and Program Management, leading early development small-molecule pipeline assets. Neil's pivotal roles at AbbVie Bioresearch Center, as Scientific Director and Director, Drug Development Project Management, significantly contributed to the development of groundbreaking immunology therapies, including RinvoqTM (upadacitinib).
Dr. Wishart holds a Ph.D. in Organic Chemistry from the University of Newcastle Upon Tyne, where he also earned a BSc in Chemistry with First-Class Honors. His impressive achievements and unwavering commitment to advancing healthcare underscore his prominence in the global biopharma sector.
Intelisci is thrilled to welcome Dr. Neil Wishart to its Scientific Advisory Board, where his wealth of experience and expertise will further strengthen the company's mission to support and empower biotechnology companies worldwide.
About Intelisci:
Intelisci is a premier Specialist Retained Search and Advisory firm dedicated to providing expert talent solutions for the biotechnology sector. With a commitment to supporting the growth and success of biotechnology companies, Intelisci connects organizations with top-tier professionals, ensuring they have the talent needed to drive innovation and make a meaningful impact on the world.
Comments